The Federal Trade Commission is requesting public input on how a wide range of common practices used by large, vertically integrated pharmacy benefit managers are impacting drug affordability. The RFI comes just days after FTC voted against launching an investigation to study the impact of PBM practices on drug prices and pharmacies . That investigation, which would have allowed FTC to subpoena information from companies, could have been much more aggressive than the new request for information. Key concerns the...